We are live on ! Find out more
ORKA

Oruka Therapeutics
ORKA

21 hedge funds and large institutions have $17.5M invested in Oruka Therapeutics in 2016 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

600% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 1

40% more funds holding

Funds holding: 15 → 21 (+6)

18% less capital invested

Capital invested by funds: $21.3M → $17.5M (-$3.84M)

75% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 4

Holders
21
Holders Change
+6
Holders Change %
+40%
% of All Funds
0.56%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
1
Reduced
4
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
PAM
Panagora Asset Management
Massachusetts
+$265K
2
BFA
BlackRock Fund Advisors
California
+$42.2K
3
Goldman Sachs
Goldman Sachs
New York
+$37.7K
4
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors
Iowa
+$35.5K
5
UBS Group
UBS Group
Switzerland
+$5.18K

Top Sellers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
-$739K
2
RA
Royce & Associates
New York
-$92.5K
3
VKH
Virtu KCG Holdings
New York
-$54K
4
Walleye Trading
Walleye Trading
New York
-$2.96K
5
TRCT
Tower Research Capital (TRC)
New York
-$2.22K
Name Holding Trade Value Shares
Change 		Change in
Stake
NMC
1
NEA Management Company
Maryland
$4.24M – – –
Franklin Resources
2
Franklin Resources
California
$3.53M – – –
VMI
3
VHCP Management II
New York
$3.13M – – –
TCM
4
Tekla Capital Management
Massachusetts
$2.35M – – –
RCM
5
RA Capital Management
Massachusetts
$1.63M -$739K -998 -28%
VM
6
VHCP Management
New York
$1.34M – – –
RA
7
Royce & Associates
New York
$443K -$92.5K -125 -15%
Vanguard Group
8
Vanguard Group
Pennsylvania
$353K – – –
PAM
9
Panagora Asset Management
Massachusetts
$224K +$265K +358 New
Deutsche Bank
10
Deutsche Bank
Germany
$109K – – –
BFA
11
BlackRock Fund Advisors
California
$38K +$42.2K +57 +1,900%
Goldman Sachs
12
Goldman Sachs
New York
$32K +$37.7K +51 New
Cambridge Investment Research Advisors
13
Cambridge Investment Research Advisors
Iowa
$30K +$35.5K +48 New
UBS Group
14
UBS Group
Switzerland
$4K +$5.18K +7 New
BIM
15
BlackRock Investment Management
Delaware
$3K +$3.7K +5 New
Bank of America
16
Bank of America
North Carolina
$2K – – –
Walleye Trading
17
Walleye Trading
New York
$1K -$2.96K -4 -80%
TRCT
18
Tower Research Capital (TRC)
New York
$1K -$2.22K -3 -75%
CFA
19
Camarda Financial Advisors
Florida
$1K +$740 +1 New
VKH
20
Virtu KCG Holdings
New York
– -$54K -73 Closed
Creative Planning
21
Creative Planning
Kansas
– +$740 +1 New

ORKA Hedge Fund Activity: Q2 2016 in Review

21 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Oruka Therapeutics (ORKA) for Q2 2016, worth a combined $17.5M — down 18% from $21.3M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new ORKA positions and 1 closed out — a net gain of 6 holders — while 1 added to existing stakes and 4 trimmed.

The largest buyer was Panagora Asset Management, opening a new position worth an estimated $265K. The largest seller was RA Capital Management, cutting an estimated $739K.

  • 21 institutional investors held Oruka Therapeutics (ORKA) as of Q2 2016, up from 15 in Q1 2016.
  • Funds reported $17.5M of Oruka Therapeutics stock for Q2 2016, down 18% quarter-over-quarter.
  • 7 funds opened new Oruka Therapeutics positions in Q2 2016 and 1 closed out, a net change of +6 holders.
  • The largest Oruka Therapeutics buyer in Q2 2016 was Panagora Asset Management, an estimated $265K added.
  • The largest Oruka Therapeutics seller in Q2 2016 was RA Capital Management, an estimated $739K sold.

Based on aggregated 13F filings for Q2 2016.